← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Schepens Eye Research Institute, Inc., The
$33,032,311
Total funding
25
Grants
Funding over time
peak $4.9M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$33,032,311 · 25
By mechanism
—$33,032,311 · 25
Investigators at Schepens Eye Research Institute, Inc., The
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
MILITARY VISION RESEARCH PROGRAM$3,380,000
· FY2008 · Department of the Army
ACTIVE CONFOCAL IMAGING SYSTEM FOR VISUAL PROSTHESES$2,999,953
· FY2016 · Department of the Army
STEROID ELUTING THERAPEUTIC CONTACT LENS..$2,098,765
· FY2019 · Defense Health Agency
MILITARY VISION RESEARCH PROGRAM$2,097,000
· FY2011 · Department of the Army
NOVEL ADHESIVE BIOMATERIALS FOR QUICK AND LONG-LASTING SUTURELESS REPAIR OF CORNEAL INJURIES$2,075,553
· FY2018 · Defense Health Agency
TOPICAL HEPATOCYTE GROWTH FACTOR FOR CORNEAL REGENERATION AND REVERSAL OF SCARRING$1,968,846
· FY2021 · Defense Health Agency
CONCOMITANT TOPICAL TREATMENT OF PAIN AND INFLAMMATION IN OCULAR INJURIES$1,475,676
· FY2022 · Defense Health Agency
A DUAL ANTIBIOTIC-STEROID DRUG-ELUTING CONTACT LENS FOR TREATMENT OF EYE INJURIES THAT CAN BE USED IN AN AUSTERE ENVIRONMENT OR PROLONGED FIELD CARE SETTING$1,469,457
· FY2021 · Defense Health Agency
TESTING THE PRECLINICAL EFFICACY OF THERAPIES FOR PROLIFERATIVE VITREORETINOPATHY$1,469,226
· FY2017 · Department of the Army
ALPHA-MELANOCYTE STIMULATING HORMONE (ALPHA945-MSH) THERAPEUTIC INTERVENTION FOR PREVENTION AND REVERSAL OF CORNEAL EDEMA FOLLOWING OCULAR INJURY$1,468,332
· FY2021 · Defense Health Agency
TOPICAL OXYGEN FOR PAN-OCULAR PROTECTION (TOPP) AGAINST SEVERE CHEMICAL INJURY$1,466,706
· FY2025 · Defense Health Agency
REHABILITATION OF VISUAL AND PERCEPTUAL DYSFUNCTION AFTER SEVERE TBI$1,429,567
· FY2011 · Department of Defense
SAFETY AND EFFICACY OF SUPERSATURATED OXYGEN EMULSION (SSOE) AS A NOVEL TOPICAL TREATMENT IN OPEN GLOBE INJURY$1,428,860
· FY2022 · Department of the Army
MILITARY VISION RESEARCH PROGRAM$1,356,000
· FY2009 · Department of the Army
MOLECULAR BLOCKADE OF LYMPHANGIOGENESIS IN PROMOTING HIGH-RISK CORNEAL TRANSPLANT SURVIVAL$1,172,077
· FY2008 · Department of the Army
DRUG ELUTING CONTACT LENSES: A TOPICAL TREATMENT FOR THE PREVENTION AND MANAGEMENT OF OCULAR WOUND INFECTIONS$999,628
· FY2015 · Department of Defense
TARGETING METABOLIC REPROGRAMMING FOR THE PREVENTION AND TREATMENT OF PROLIFERATIVE VITREORETINOPATHY.$981,869
· FY2019 · Defense Health Agency
DEVELOPMENT OF A VISION ASSISTIVE DEVICE FOR VETERANS WITH TBI-ASSOCIATED VISUAL DYSFUNCTIONS$933,820
· FY2010 · Department of Defense
SUPERSATURATED OXYGEN EMULSION AS A NOVEL TOPICAL TREATMENT FOR OCULAR CHEMICAL INJURY. NEW AWARD.$860,831
· FY2020 · Defense Health Agency
ADVANCING SUPERSATURATED OXYGEN EMULSION AS A TOPICAL TREATMENT FOR OCULAR CHEMICAL INJURY IN RABBITS$512,199
· FY2022 · Defense Health Agency